Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Clin Cancer Res ; 19(5): 1190-6, 2013 Mar 01.
Article in English | MEDLINE | ID: mdl-23329812

ABSTRACT

PURPOSE: Data about the prognostic factors of soft-tissue leiomyosarcomas and their correlation with molecular profile are limited. EXPERIMENTAL DESIGN: From 1990 to 2010, 586 adult patients with a primary soft-tissue leiomyosarcoma were included in the French Sarcoma Group (GSF) database after surgery of the primary tumor. Multivariate analyses were conducted by Cox regression model in a backward stepwise procedure. Genetic profiling was conducted for 73 cases. RESULTS: Median age was 59 years (range, 21-98 years). The median follow-up of patients alive was 46 months. The 5-year metastasis-free survival (MFS) rate was 51% (95% location and grade > I were independent adverse prognostic factors for MFS). The 5-year overall survival (OS) rate was 63% [95% confidence interval (CI), 59-67]. On multivariate analysis, age ≥ 60 years old, tumor size > 5 cm, deep location, and grade > I were independent adverse prognostic factors for OS. Molecular profiling identified specific clusters with activation of different biologic pathways: retroperitoneal leiomyosarcomas are characterized by overexpression of genes involved in muscle differentiation and nonretroperitoneal leiomyosarcomas characterized by overexpression of genes mainly involved in extracellular matrix, wounding, and adhesion pathways. The CINSARC signature but not comparative genomic hybridization (CGH) profiling was predictive of outcome. CONCLUSION: Soft-tissue leiomyosarcomas represent a heterogeneous group of tumors with at least two categories, retroperitoneal and extremities leiomyosarcomas, having specific clinical outcome and molecular features. Future clinical trials should consider this heterogeneity for a better stratification of patients.


Subject(s)
Biomarkers, Tumor/genetics , Gene Expression Profiling , Leiomyosarcoma/classification , Neoplasm Recurrence, Local/genetics , Soft Tissue Neoplasms/classification , Adult , Aged , Aged, 80 and over , Cohort Studies , Combined Modality Therapy , Comparative Genomic Hybridization , Female , Follow-Up Studies , Humans , Leiomyosarcoma/genetics , Leiomyosarcoma/pathology , Male , Middle Aged , Neoplasm Grading , Neoplasm Recurrence, Local/diagnosis , Oligonucleotide Array Sequence Analysis , Prognosis , Soft Tissue Neoplasms/genetics , Soft Tissue Neoplasms/pathology , Survival Rate , Young Adult
2.
Am J Surg Pathol ; 31(9): 1387-402, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17721195

ABSTRACT

Low-grade fibromyxoid sarcomas (LGFMS) bear either the t(7,16) (q32-34;p11) or t(11,16) (p11;p11) translocations, resulting in FUS-CREB3L2 or FUS-CREB3L1 fusions, respectively. Heretofore, fusion transcripts were mainly detected in frozen tissues, using reverse transcription-polymerase chain reaction. In this study, we aimed to develop a reliable method to detect these in paraffin-embedded tissues, and to examine the clinicopathologic characteristics of a series of translocation-positive LGFMS. Sixty-three neoplasms with typical morphologic features of LGFMS and 66 non-LGFMS tumors selected for their resemblance to LGFMS (LGFMS-like tumors) were examined. RNA of sufficient quality could be extracted from 111/129 (86%) cases (59 LGFMS, 52 non-LGFMS). Of all, 48/59 (sensitivity, 81%) LGFMS contained detectable transcripts (45 FUS-CREB3L2, 3 FUS-CREB3L1). Most relevant clinicopathologic features of fusion-positive LGFMS included predominance in lower extremities (22/48; thigh: 13/48), deep situation (46/48), and occasional presence of unusual histologic features, for example, hypercellular areas (16/48), foci of epithelioid cells (13/48), and giant rosettes (6/48). Most tumors expressed EMA (41/45), at least focally, CD99 (38/41) and bcl-2 (36/41) while being essentially negative for CD34 (2/45), mdm2 (1/41), smooth muscle actin (1/45), S100 protein (0/46), desmin (0/44), h-caldesmon (0/42), keratins (0/44), and CD117 (0/40). Eleven presumed LGFMS were fusion negative. Of all, 7/52 non-LGMFS neoplasms contained FUS-CREB3L2 transcripts, of which 4 had been diagnosed as sclerosing epithelioid fibrosarcoma. In conclusion, FUS-CREB3L1/L2 fusion transcripts can be detected in paraffin-embedded LGFMS in a sensitive manner, using reverse transcription-polymerase chain reaction. Most fusion-positive LGFMS are EMA-positive and CD34/S100/smooth muscle actin negative. The presence of epithelioid cells and fusion transcripts in both LGFMS and a subset of sclerosing epithelioid fibrosarcoma suggest that these neoplasms might be related.


Subject(s)
Basic-Leucine Zipper Transcription Factors/genetics , Biomarkers, Tumor/genetics , Cyclic AMP Response Element-Binding Protein/genetics , Epithelioid Cells/pathology , Fibroma/diagnosis , Fibrosarcoma/diagnosis , Gene Expression Regulation, Neoplastic , Nerve Tissue Proteins/genetics , RNA-Binding Protein FUS/genetics , Translocation, Genetic , Adolescent , Adult , Aged , Base Sequence , Biomarkers, Tumor/analysis , Child , Female , Fibroma/chemistry , Fibroma/genetics , Fibroma/pathology , Fibrosarcoma/chemistry , Fibrosarcoma/genetics , Fibrosarcoma/pathology , Humans , In Situ Hybridization, Fluorescence , Male , Middle Aged , Molecular Sequence Data , Neoplasm Invasiveness , Paraffin Embedding , Predictive Value of Tests , RNA, Messenger/analysis , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity
3.
Cancer ; 107(5): 1055-64, 2006 Sep 01.
Article in English | MEDLINE | ID: mdl-16878328

ABSTRACT

BACKGROUND: Clear cell sarcoma (CCS) is a rare tumor with a very poor prognosis that occurs predominantly in the distal extremities of young adults. Most patients bear the t(12;22) reciprocal translocation, which involves the EWS and ATF1 genes. The diagnosis of CCS usually is easy but may be challenging in unusual sites, and the detection of EWS-ATF1 fusion transcripts is helpful to rule out a metastatic melanoma. METHODS: Forty-four patients with CCS and 14 conventional melanomas were examined for the presence of EWS-ATF1 transcripts by using real-time polymerase chain reaction (PCR) analysis on paraffin embedded tissues, including frozen samples for 9 CCS samples and 9 melanoma samples. Prior to molecular analysis, the diagnosis of CCS was considered certain in 35 patients and as probable in 9 patients on the basis of location, histologic features, and immunohistochemical profile. Treatment modalities and follow-up were available for 41 patients with CCS. RESULTS: EWS-ATF1 fusion transcripts were detected in 38 paraffin embedded CCS tissues (86% of all samples; 93% of interpretable samples), 3 samples (7%) were negative, and 3 samples (7%) were considered uninterpretable. Fusion transcripts were detected in 7 of 9 samples for which the diagnosis of CCS was considered probable. EWS-ATF1 transcripts were not detected in the 14 samples of melanoma. Results from frozen tissues were concordant with those from all corresponding paraffin embedded samples. Twenty-eight of 41 patients (68%) experienced lymph node and/or distant metastasis, and the 5 year-survival rate was 44%. Mitotic index and histologic grade were predictive of survival and distant metastasis. CONCLUSIONS: The results of this study showed that the molecular detection of EWS-ATF1 fusion transcript by real-time PCR on paraffin embedded tissues is a sensitive and specific method for the diagnosis of CCS. It is an efficient tool for the diagnosis of unusual tumors, especially with regard to its distinction from melanoma. The current results also confirmed the poor prognosis for patients with this tumor type. Mitotic index and grade were predictive factors for survival and distant metastasis.


Subject(s)
Oncogene Proteins, Fusion/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Sarcoma, Clear Cell/diagnosis , Transcription Factors/genetics , Adolescent , Adult , Child , Computer Systems , Female , France , Humans , Immunohistochemistry , Male , Melanoma/diagnosis , Oncogene Proteins, Fusion/analysis , Paraffin Embedding , Prognosis , Sarcoma, Clear Cell/genetics , Survival Analysis , Transcription Factors/analysis
4.
Radiother Oncol ; 73(3): 313-9, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15588876

ABSTRACT

PURPOSE: To analyze the management and clinical outcome of patients treated for a first isolated local recurrence of soft tissue sarcomas (trunk or extremities) and to identify prognosis factors. METHODS AND MATERIAL: Between 1980 and 1999, 83 adult patients were included in the study. Mean age was 61 years. Mean tumor size was 6 cm. Most sarcomas were located in extremities (n=74), were deep (n=60), and proximal (n=53); 30 involved nerves or vessels. Histologic subtypes were mainly grade 2 (42%) or 3 (36%) histiocytofibrosarcomas (49%) and liposarcomas (20%). Surgical treatment of recurrences consisted in wide excision (29 cases), marginal resection (43 cases), 5 patients requiring amputation. Final results were R0 (n=33), R1 (n=47) or R2 (n=3) resection. Besides surgery, 6 patients received neo-adjuvant and 7 others adjuvant chemotherapy. Twenty three patients received post-operative external beam radiotherapy (EBRT) (mean dose 55 Gy) and 26 interstitial 192Ir low dose rate brachytherapy (BCT) (mean dose 45 Gy for BCT alone, 22 Gy when associated with EBRT), 19 patients being re-irradiated. RESULTS: Mean follow up was 13 years. Thirty-seven (45%) patients relapsed, 62% of whom presenting an isolated local recurrence. Nineteen patients developed distant metastases. Multivariate analysis showed only tumor depth (P=0.05) and re-resection for primary R1 resection (P=0.018) being independent prognosis factors for tumor control, radiotherapy (EBRT and/or BCT) being significant in univariate analysis (P=0.05). Overall survival rate was 73%, 54%, and 47% at, respectively, 3.5 and 10 years, and was 65%, 35% and 32% after a further local recurrence. Multivariate analysis showed trunk (P=0.0001) or inferior extremity locations (P=0.023), symptomatic (P=0.001), high grade (P=0.01), deep (P=0.01) tumors, and the occurrence of a further local failure (P=0.004) as unfavorable characteristics for overall survival. CONCLUSIONS: A first isolated local recurrence of STS increases mainly the risk of a subsequent local relapse. Quality of local treatment is decisive. When a conservative treatment is feasible, it should combine surgical resection and radiotherapy, BCT being the best suited in previously irradiated patients. Efforts have to be pursued to increase quality of the treatment of primary tumors, at best performed in centers that have expertise in this field.


Subject(s)
Fibrosarcoma/pathology , Fibrosarcoma/radiotherapy , Liposarcoma/pathology , Liposarcoma/radiotherapy , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/radiotherapy , Sarcoma/pathology , Sarcoma/radiotherapy , Adult , Aged , Aged, 80 and over , Female , Fibrosarcoma/surgery , Humans , Liposarcoma/surgery , Male , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness , Neoplasm Recurrence, Local/surgery , Neoplasm Staging , Retrospective Studies , Risk Factors , Sarcoma/surgery
5.
Obstet Gynecol ; 104(5 Pt 2): 1147-9, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15516431

ABSTRACT

BACKGROUND: Endometrial stromal sarcoma arising from extrauterine endometriosis is a rare and not easily diagnosed tumor. We present a case arising from sciatic nerve endometriosis in a 50-year-old woman. CASE: The patient had a long history of endometriosis and presented with a left buttock mass and motor deficit. Magnetic resonance imaging showed a large tumor of the sciatic nerve with pelvic extension. She underwent total hysterectomy, bilateral salpingo-oophorectomy, and excision of pelvic endometriotic pockets, allowing the diagnosis of low-grade endometrial stromal sarcoma arising from endometriosis. She received systemic chemotherapy, gonadotropin-releasing hormone agonist therapy, and palliative radiation therapy, but her disease progressed. CONCLUSION: Aggressive endometriosis raises important diagnostic and therapeutic difficulties and may correspond to misdiagnosed rare malignant neoplasms, which should be treated.


Subject(s)
Cell Transformation, Neoplastic/pathology , Endometrial Neoplasms/pathology , Endometriosis/pathology , Sarcoma, Endometrial Stromal/pathology , Sciatic Nerve/pathology , Biopsy, Needle , Combined Modality Therapy , Disease Progression , Endometrial Neoplasms/therapy , Endometriosis/physiopathology , Fatal Outcome , Female , Humans , Immunohistochemistry , Laparotomy , Magnetic Resonance Imaging , Middle Aged , Neoplasm Staging , Radiotherapy, Adjuvant , Sarcoma, Endometrial Stromal/therapy
6.
Am J Surg Pathol ; 26(5): 601-16, 2002 May.
Article in English | MEDLINE | ID: mdl-11979090

ABSTRACT

The clinicopathologic and immunohistochemical features of 63 pleomorphic liposarcomas are presented. There were 35 men and 28 women (median age 63 years; range 18-93 years). Tumor size ranged from 2 to 23 cm (median 10 cm). Tumor locations included lower extremity (36.5%), especially the thigh (28.5%), limb girdles (17.5%), upper extremity (16%), thoracoabdominal wall (9.5%), and internal trunk (20.5%). A total of 75% were deep seated and/or extracompartmental. Histologically, lesions show a varying combination of lipogenic and nonlipogenic areas characterized by malignant fibrous histiocytoma-like, round cell liposarcoma-like, and/or epithelioid/carcinoma-like features. A pericytic pattern was focally present in 15 (24%) tumors. Eighteen (29%) lesions were grade 2, and 45 (71%) were grade 3 sarcomas. Tumor necrosis was observed in 51 (81%) cases, vascular invasion in three, and mitotic counts ranged from 3 to 124 per 10 high power fields (median 25). Lipogenic areas were S-100 protein immunoreactive, at least focally, in 20 of 42 (48%) cases. Nonlipogenic areas showed focal reactivity for smooth muscle actin (24 of 49; 49%), desmin (9 of 48; 19%), CD34 (18 of 45; 40%), S-100 protein (5 of 49, 10%), CD68 (6 of 46, 13%), and epithelial membrane antigen (13 of 49, 26.5%). Epithelioid areas showed epithelial membrane antigen (4 of 11; 36%) but not cytokeratin (0 of 11) reactivity. Treatment procedures in 51 patients consisted of simple tumorectomy (16) and wide excision (33). Five and 31 patients received neoadjuvant and adjuvant chemotherapy and/or radiation therapy, respectively. Follow-up (48 patients, range 7-276 months; median 38 months) showed a 45% local recurrence rate and a 42.5% metastasis rate, metastases occurring mostly in lungs and pleura. Seventeen patients (35%) died of disease, of whom none was metastatic at diagnosis. Five-year overall, metastasis-free, and local recurrence-free survivals were 57%, 50%, and 48%, respectively. Patient age > or =60 years, truncal tumor location, deep situation, tumor size >5 cm, vascular invasion, and incomplete tumor excision were significant adverse prognostic factors. Tumor grade and histology did not affect patient outcome. In conclusion, pleomorphic liposarcoma is a rare, often deep-seated and limb-based aggressive and metastasizing neoplasm of late adulthood. It shows a wide range of morphologic appearances, but tumor grade and histology have no effect on patient outcome.


Subject(s)
Liposarcoma/pathology , Soft Tissue Neoplasms/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Disease-Free Survival , Female , Humans , Immunohistochemistry , Liposarcoma/chemistry , Liposarcoma/mortality , Liposarcoma/surgery , Male , Middle Aged , Neoplasm Proteins/analysis , Soft Tissue Neoplasms/chemistry , Soft Tissue Neoplasms/mortality , Soft Tissue Neoplasms/surgery , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...